Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment

Nav

General Info

Geography

United Kingdom (GBR)

Coverage type

Country

Time period covered

01/2010 - 12/2021

Data type

Scientific literature

Keywords

Diabetes, Trachea, bronchus, and lung cancers

Citation

Authors

Mulla K, Farag S, Moore B, Matharu S, Young K, Larkin J, Popat S, Morganstein DL

Journal

Diabet Med

Volume

Issue

Pages

e15053

Publication year

2023

Suggested citation

Mulla K, Farag S, Moore B, Matharu S, Young K, Larkin J, Popat S, Morganstein DL. Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment. Diabet Med. 2023; 40(4): e15053.

DOI

101111dme15053

PMID

36696014

GHDx Entry last modified on: Dec 12, 2023

Header sites

Search form

Main menu

Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment

Nav